Upcoming Global IPOs
Ingenia Therapeutics (Ticker: 952509 KS) is a U.S.-based biotechnology company developing treatments that repair and protect small blood vessels damaged by disease. Its drug candidates are being studied for retinal diseases, chronic kidney disease, glaucoma, cancer and pulmonary hypertension.
Ingenia plans to list on South Korea’s KOSDAQ market on August 18, 2026. The company will offer 5 million new shares at KRW 12,000 per share, raising KRW 60 billion, or approximately $41 million. The offering values the company at around $409 million after listing. Samsung Securities is the sole lead underwriter.
According to published terms, the IPO proceeds will be used to advance clinical trials, develop additional drug candidates and expand partnerships with global pharmaceutical and biotechnology companies. Ingenia’s lead retinal disease treatment, IGT-427, was licensed to EyeBio in 2022. EyeBio was later acquired by Merck & Co., which is now leading late-stage clinical development of the treatment.
The IPOX® Newsletters
IPOX® in the News
Reuters reports that Londian Wason’s NYSE debut valued the Chinese copper foil maker at about $2.01 billion, marking the largest U.S. IPO by a Chinese company in more than a year. IPOX® Research Associate Lukas Muehlbauer cautioned that the strong first-day performance, supported by a very low float and potential scarcity premium, should not be viewed as proof of a broader reopening for larger Chinese IPOs. He also highlighted potential future supply risks and customer concentration concerns for longer-term investors.
IPOX® Associate Muehlbauer was quoted in Reuters on Londian Wason’s planned U.S. IPO, which targets a valuation of up to $1.7 billion and could become the largest New York listing by a Chinese company in more than a year. He said the relatively small offering would be encouraging rather than signal a definitive market reopening, while highlighting stronger growth, profitability, battery demand, and investor concerns over the company’s reliance on a limited number of major customers for future growth prospects.
IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Westinghouse Electric’s confidential U.S. IPO filing. He said the company’s investor appeal comes from offering exposure to nuclear growth through an established operating business and a well-known American industrial name. Muehlbauer added that energy-security concerns and rising electricity demand from data centers have improved market sentiment toward nuclear power.
IPOX® CEO Josef Schuster was featured in Bloomberg's ECM Watch, discussing muted U.S. IPO debuts and rising equity risk. Following mixed first-day performances from Jersey Mike’s and Reformation, Schuster said elevated risk is pressuring the IPO market and making investors more selective. He added that prospective issuers may need greater flexibility on pricing expectations and fundraising targets. Bloomberg also cited the IPOX® 100 U.S. as a benchmark for recent large U.S. IPOs and spinoffs amid volatile market conditions.
IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Jersey Mike’s NYSE debut, noting that raising roughly $1 billion showed investors remain willing to back large, established consumer brands. The sandwich chain’s shares opened 8.7% below their $23 IPO price, valuing the company at about $6.7 billion. Muehlbauer also cautioned against overinterpreting the first-day decline, citing broader market volatility as U.S. IPO activity continues to recover across technology, defense, industrial, consumer, and retail sectors this year after a prolonged slowdown.
The IPOX® Update
Global IPO activity is building across major markets, led by large planned offerings from Dangote Refinery, Moonshot AI, Nscale and Airtel Money. U.S. listings include Robinhood Ventures Fund II and Londian Wason, while Europe may see major transactions from KNDS and Kazakhstan’s KTZ. Hong Kong remains active with Moonshot AI and Sichuan Biokin, while Qatar’s Dandy advances its offering. Overall, the pipeline highlights strong investor interest in AI, infrastructure, financial services, industrials, biotechnology and energy-related issuers worldwide.
Global IPO activity spans major U.S., European and Asia-Pacific deals, led by potential multibillion-dollar listings from CyrusOne, Westinghouse and Nscale. Recent U.S. debuts from Jersey Mike’s and Reformation showed cautious investor sentiment, increasing pressure on pricing and fundraising expectations. Smaller transactions include Braveheart Bio, Space-Eyes, Karman Line, Vogenx and NASN Intelligent Tech. Across sectors, investors remain interested in established brands, nuclear energy, data centers, biotechnology, defense technology and artificial-intelligence infrastructure, despite heightened volatility and greater scrutiny of financial performance metrics.
Jersey Mike’s leads the pipeline with a potential $1.09 billion NYSE offering, followed by Reformation, Amapá Minerals and Saudi lubricant producer Petrolube. Other notable candidates include Lyntris, AlphaSense, Moonshot AI, AgiBot, TAWAL and Pepkor’s planned fintech spin-off. Together, the transactions span North America, Asia-Pacific, MENA and Africa, reflecting continued demand for sizable public-market opportunities across diverse industries and global markets.